EC
CSTL icon

EntryPoint Capital’s Castle Biosciences CSTL Stock Holding History

EntryPoint Capital’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$213K Buy
+8,942
New +$199K 0.05% 674
2025
Q2 		– Sell
-20,432
Closed -$409K – 655
2025
Q1 		$409K Sell
20,432
-8,712
-30% -$216K 0.19% 181
2024
Q4 		$777K Buy
29,144
+19,862
+214% +$605K 0.33% 14
2024
Q3 		$265K Buy
+9,282
New +$236K 0.15% 303

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EntryPoint Capital's CSTL Position: Q2 2026 in Review

EntryPoint Capital opened a new position in Castle Biosciences (CSTL) in Q2 2026: 8,942 shares worth $213K. The stake represents 0.05% of the portfolio and ranks #674 among its holdings. This is a return to the name: EntryPoint Capital previously reported a position in CSTL as recently as Q1 2025.

EntryPoint Capital first reported a position in CSTL in Q3 2024 and has held it in 4 quarters since. The position peaked at $777K in Q4 2024. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • EntryPoint Capital held 8,942 shares of Castle Biosciences worth $213K as of Q2 2026.
  • Castle Biosciences was a new EntryPoint Capital position in Q2 2026.
  • Castle Biosciences made up 0.05% of EntryPoint Capital's portfolio in Q2 2026, its #674 holding.
  • EntryPoint Capital first reported a position in Castle Biosciences in Q3 2024 and has held it in 4 quarters since.
  • EntryPoint Capital's Castle Biosciences position peaked at $777K in Q4 2024.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.